Trilaciclib to Protect the Blood System in Limited-Stage Small Cell Lung Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 3 randomized trial evaluating trilaciclib versus placebo in patients with limited-stage small cell lung cancer. Participants will receive trilaciclib or saline as a control, alongside standard treatment, to see if the drug reduces myelosuppression and related safety issues. The study includes adults with confirmed limited-stage disease who have recovered from prior surgery and have measurable disease, excluding those with extensive-stage disease or certain health risks. Primary outcomes focus on myelosuppression and safety, with secondary assessments of efficacy and tolerability. The trial is sponsored by Pharmacosmos A/S with a single investigational site in Oakland, California.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Confirmed diagnosis of Limited-Stage Small Cell Lung Cancer
* Complete recovery from prior anti-tumor surgical procedures
* Measurable and evaluable disease through tumor assessment
* Willingness to participate and sign informed consent form

Exclusion Criteria:

* Extensive Stage Small Cell Lung Cancer
* Active cardiovascular disease
* Known hypersensitivity to trilaciclib, etoposide, carboplatin, cisplatin or any component in their formulations
* Pregnant or nursing women

Where it's running

• Pharmacosmos Investigational Site
  Oakland, California, United States Recruiting

Study contacts

• Study coordinator: Pharmacosmos A/S Clinical and non-clinical research
• Email: info@pharmacosmos.com
• Phone: +4559485959

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Shrinkage-free combo in LS-SCLC: SHR-7787 plus SHR-1316

  This trial tests whether the combo of SHR-7787 and SHR-1316 can help adults with unresectable limited-stage small cell lung cancer after prior platinum-based chemo and radiation.

  Recruiting Phase 2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Jinan, Shandong · NCT07798947

• Tarlatamab as maintenance treatment after chemo-radiotherapy for limited-stage small-cell lung cancer.

  This trial will test whether giving tarlatamab after chemo-radiotherapy helps people with limited-stage small-cell lung cancer stay progression-free longer.

  Recruiting at 20 sites Phase 2 Fundación GECP · Albacete, Albacete and 19 other locations · NCT07242547

• Durvalumab consolidation after chemoradiation for limited-stage small-cell lung cancer in China

  This project will test durvalumab given after chemoradiation in people with limited‑stage small‑cell lung cancer who have not progressed, to see how well it works and how safe it is in routine care.

  Recruiting at 20 sites AstraZeneca · Beijing and 20 other locations · NCT07161388

• Probiotics plus intensified hyperfractionated chemoradiation with adebrelimab maintenance for limited-stage small cell lung cancer

  This trial tests whether adding probiotics and an intensified hyperfractionated radiotherapy plan to chemo, followed by adebrelimab maintenance, helps people with limited-stage small cell lung cancer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06943235

• Combination therapy for limited-stage small cell lung cancer

  This study is testing a new combination of immunotherapy and chemotherapy to see if it can help people with limited-stage small cell lung cancer have better treatment results.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai · NCT06256237

• Combination treatment for extensive stage small cell lung cancer

  This study is testing a new combination treatment for people with extensive stage small cell lung cancer to see if it helps them live longer and feel better.

  Recruiting at 4 sites Phase 2 Hoosier Cancer Research Network · Indianapolis, Indiana and 3 other locations · NCT05903092

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.